Plant Name: Avena sativa
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.148E-08 | 2.272E-05 | CA1, CA12, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9, TP53 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.942E-08 | 5.339E-05 | CYP2C19, CYP2C9, CYP2D6 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.723E-27 | 3.752E-23 | CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 4.066E-06 | 5.208E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 8.614E-06 | 7.989E-03 | CYP2C19, CYP2C9, CYP2D6 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.399E-21 | 1.523E-17 | CA1, CA12, CA14, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 7.341E-20 | 3.996E-16 | CA1, CA12, CA2, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 7.870E-27 | 7.634E-25 | CA12; CA1; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 6.624E-05 | 3.213E-03 | CYP2C9; CYP2D6; CYP2C19 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 2.790E-04 | 7.648E-03 | CYP2C9; CYP2D6; CYP2C19 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 4.930E-04 | 8.148E-03 | RAB9A; TP53; NFKB1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 3.154E-04 | 7.648E-03 | CA2; CA4 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 2.261E-03 | 2.557E-02 | CYP2C9; GAA; ALPL; CYP2C19; HSD17B10; XDH |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 5.040E-04 | 8.148E-03 | CYP2C9; CYP2C19 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 2.294E-03 | 2.557E-02 | CYP2C9; CYP2C19 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 3.004E-03 | 2.557E-02 | MAPT; TP53; NFKB1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 2.595E-03 | 2.557E-02 | TP53; NFKB1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 3.164E-03 | 2.557E-02 | TP53; NFKB1 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 3.164E-03 | 2.557E-02 | CYP2C9; CYP2D6 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 4.662E-03 | 3.015E-02 | TP53; NFKB1 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 4.360E-03 | 3.015E-02 | TP53; NFKB1 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 5.185E-03 | 3.144E-02 | TP53; NFKB1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 3.973E-03 | 2.964E-02 | CYP2C9; CYP2C19 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 6.193E-03 | 3.337E-02 | PFKFB3; NFKB1 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 8.318E-03 | 4.034E-02 | TP53; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.118E-02 | 4.929E-02 | TP53; NFKB1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 8.318E-03 | 4.034E-02 | TP53; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.013E-02 | 4.681E-02 | TP53; NFKB1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 5.737E-03 | 3.274E-02 | XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
| C00-D49: Neoplasms | Colon cancer | C50 | ALPL |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; CYP2D6 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| NA: NA | Edema | NA | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH |
| A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1 |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| C00-D49: Neoplasms | Cancer | C00-C96 | TP53; CA1; CA9; NFKB1 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | TP53; CA9; PFKFB3 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |